Dosage & Protocols

Retatrutide is a triple agonist acting on GIP, GLP-1 and glucagon receptors, under investigation for metabolic research applications. Phase 2 data demonstrated significant changes in body composition over 48 weeks. Administer subcutaneously (abdomen, thigh or upper arm) on the same day each week.

💡 Research protocols recommend a minimum 4-week period at each dose level before escalation to assess tolerability.

Based on: Jastreboff AM et al. NEJM 2023 — Read study

Tirzepatide is a dual GIP/GLP-1 receptor agonist studied for its effects on metabolic parameters and body composition. The SURMOUNT-1 trial demonstrated significant outcomes over 72 weeks. Administer subcutaneously once weekly on a consistent day.

💡 Research protocols follow a fixed escalation: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, with a minimum 4 weeks at each level.

Based on: Jastreboff AM et al. NEJM 2022 — Read study

Cagrilintide is a long-acting amylin analogue under investigation for metabolic research. Phase 2 data showed notable changes in body composition parameters over 26 weeks, with additional research ongoing in combination with GLP-1 agonists. Administer subcutaneously once weekly on a consistent day.

💡 Research combining cagrilintide with semaglutide (CagriSema) is ongoing — the combination targets complementary receptor pathways.

Based on: Enebo LB et al. Lancet 2021 — Read study

BPC-157 is a pentadecapeptide derived from human gastric juice, studied in preclinical models for its effects on tissue repair, angiogenesis and gut mucosal integrity. Administer subcutaneously, typically proximal to the research site. Oral administration is used in gut-related research models.

💡 Commonly studied alongside TB-500 in combination protocols targeting complementary repair pathways.

Based on: Sikiric P et al. Curr Pharm Des 2018 — Read study

TB-500 is a synthetic fragment of Thymosin Beta-4, studied for its role in actin regulation, cell migration and systemic tissue remodelling in preclinical models. Acts systemically rather than locally. Administer subcutaneously.

💡 Frequently studied in combination with BPC-157 — our pre-blended vials provide a standardised fixed-ratio protocol.

Based on: Goldstein AL et al. Expert Opin Biol Ther 2012 — Read study

GHK-Cu is a naturally occurring plasma tripeptide-copper complex studied for its role in wound healing, collagen synthesis, anti-inflammatory activity and skin remodelling. Plasma levels decline with age. Administer subcutaneously or apply topically for localised dermal research applications.

💡 Frequently studied alongside Epithalon in longevity and cellular repair research protocols.

Based on: Pickart L et al. Int J Mol Sci 2018 — Read study

CJC-1295 with DAC is a GHRH analogue with an extended half-life (~8 days) due to albumin binding. Research demonstrates sustained elevation of GH and IGF-1 in study subjects. Administer subcutaneously, typically in the evening.

💡 Commonly studied in combination with Ipamorelin — the pairing targets both GHRH and GHRP receptor pathways for a synergistic GH pulse.

Based on: Ionescu M et al. J Clin Endocrinol Metab 2006 — Read study

Ipamorelin is a selective GHRP with minimal effect on cortisol and prolactin — a key distinguishing feature from earlier generation GHRPs. Stimulates GH secretion via the ghrelin receptor (GHSR). Administer subcutaneously 30–60 minutes prior to the sleep phase in research protocols.

💡 Commonly co-administered with CJC-1295 in research — the combination targets both GHRH and GHRP pathways simultaneously.

Based on: Raun K et al. Eur J Endocrinol 1998 — Read study

IGF-1 LR3 is a long-acting analogue of IGF-1 with reduced IGFBP binding, resulting in a significantly extended half-life (~20–30 hours vs ~12 minutes for native IGF-1). Studied for effects on cellular proliferation, protein synthesis and nutrient partitioning. Administer subcutaneously in post-exercise research windows.

⚠️ Research protocols note hypoglycaemia risk — monitoring of blood glucose is recommended, particularly during initial administrations.

Based on: Francis GL et al. Biochem J 1988 — Read study

AOD-9604 is the C-terminal fragment of hGH (176–191) responsible for lipolytic activity, studied for its effects on fat metabolism without the anabolic or diabetogenic properties of full growth hormone. Does not affect IGF-1 levels. Administer subcutaneously in a fasted state in research protocols.

💡 Research notes no observed impact on blood glucose or insulin sensitivity, distinguishing it from full HGH in metabolic studies.

Based on: Heffernan MA et al. Int J Obes 2001 — Read study

Tesamorelin is an FDA-approved GHRH analogue (Egrifta) with demonstrated efficacy in clinical trials for HIV-associated lipodystrophy. Stimulates endogenous GH release, with observed reductions in visceral adipose tissue of ~15% over 26 weeks. Administer subcutaneously in the abdomen, rotating injection sites.

💡 Fixed-dose protocol — 1mg daily with no titration required, making it one of the more straightforward GHRH research compounds.

Based on: Falutz J et al. NEJM 2007 — Read study

DSIP is an endogenous neuropeptide studied for its role in sleep architecture regulation, specifically slow-wave (delta) sleep. Research also notes stress-protective and mild analgesic properties in study models. Administer subcutaneously approximately 30–60 minutes prior to the sleep phase.

💡 Research protocols typically employ intermittent rather than continuous administration to maintain receptor responsiveness.

Based on: Graf MV et al. Neurosci Biobehav Rev 1984 — Read study

Selank is a synthetic heptapeptide analogue of tuftsin, studied in Russian clinical research for anxiolytic and nootropic properties without sedation or dependence potential. Research notes BDNF upregulation and modulation of serotonin metabolism. Administer intranasally or subcutaneously per research protocol.

💡 Intranasal administration achieves rapid CNS uptake — commonly employed in research protocols requiring fast onset.

Based on: Semenova TP et al. Zh Nevrol Psikhiatr 2009 — Read study

Semax is an ACTH-derived heptapeptide studied for neuroprotective and nootropic properties. Research demonstrates upregulation of BDNF, NGF and serotonin metabolism, with clinical applications explored in Russia for over two decades. Administer intranasally or subcutaneously per research protocol.

💡 Intranasal administration is most widely documented in research literature for CNS uptake efficiency.

Based on: Grigoriev VV et al. Zh Nevrol Psikhiatr 2014 — Read study

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the St Petersburg Institute of Bioregulation, studied for its effects on telomerase activation and telomere elongation in somatic cells. Over 15 years of clinical research data from Russian institutes. Administer subcutaneously once daily over a defined course period.

💡 Research protocols employ short intensive courses (10–20 days) rather than continuous administration, typically conducted twice yearly.

Based on: Khavinson VK et al. Bull Exp Biol Med 2003 — Read study

NAD+ is a coenzyme essential for mitochondrial function, DNA repair and sirtuin activation. Research demonstrates significant decline with age, with supplementation studied for effects on cellular energetics and metabolic function. Administer subcutaneously for systemic replenishment in research protocols.

💡 Research indicates consistent daily administration maintains more stable plasma NAD+ levels compared to intermittent dosing.

Based on: Rajman L et al. Cell Metab 2018 — Read study

SS-31 (Elamipretide) is a mitochondria-targeted antioxidant peptide that selectively concentrates in the inner mitochondrial membrane. Research demonstrates reduction of oxidative stress, improvement in cristae structure and restoration of ATP synthesis efficiency. Phase 2 trials conducted in heart failure and Barth syndrome. Administer subcutaneously.

💡 Research applications include mitochondrial dysfunction, cardiac research models and age-associated bioenergetic decline.

Based on: Szeto HH. Br J Pharmacol 2014 — Read study

MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis via AMPK activation. Research demonstrates effects on insulin sensitivity, oxidative metabolism and exercise capacity in preclinical models. Endogenous levels decline with age and sedentary behaviour. Administer subcutaneously.

💡 Preclinical data suggests amplified effects when combined with aerobic exercise protocols — a frequently studied combination in metabolic research.

Based on: Lee C et al. Cell Metab 2015 — Read study

Glutathione (GSH) is the primary endogenous antioxidant tripeptide, studied for its role in oxidative stress modulation, hepatic detoxification and immune function. Plasma levels decline with age and metabolic stress. Injectable administration bypasses first-pass metabolism for superior bioavailability vs oral forms. Administer subcutaneously.

💡 Frequently studied alongside NAD+ in antioxidant and cellular health research protocols due to complementary mechanisms of action.

Based on: Sinha R et al. Eur J Nutr 2018 — Read study

KPV is the C-terminal tripeptide of α-MSH, studied for anti-inflammatory properties via NF-κB pathway inhibition and pro-inflammatory cytokine reduction. Research applications include gut mucosal integrity, dermal inflammation models and systemic inflammatory research. Administer subcutaneously or orally for gastrointestinal research models.

💡 Research indicates KPV is stable through the gastrointestinal tract, making oral administration viable for intestinal research models.

Based on: Dalmasso G et al. Infect Immun 2008 — Read study

PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist (MC3R/MC4R) studied for its central nervous system-mediated effects on sexual function. Acts via hypothalamic pathways rather than vascular mechanisms. Approved as Vyleesi for HSDD in premenopausal women. Administer subcutaneously 45–90 minutes prior to the research window.

⚠️ Research protocols note nausea as the most commonly reported adverse event — antiemetic pre-treatment is documented in clinical studies. Begin at the lowest dose to assess individual response.

Based on: Clayton AH et al. Obstet Gynecol 2016 — Read study

Melanotan II is a synthetic melanocortin receptor agonist studied for its effects on melanogenesis and MC receptor activity. Research notes dose-dependent melanin production in response to UV exposure, alongside MC3R/MC4R-mediated effects. Administer subcutaneously.

⚠️ Research protocols strongly recommend low starting doses (0.1mg) with gradual titration. Any pigmented lesions present prior to research use should be evaluated by a dermatologist.

Based on: Dorr RT et al. Life Sci 1996 — Read study

Kisspeptin-10 is a key regulator of the hypothalamic-pituitary-gonadal (HPG) axis, studied for its role in GnRH stimulation and subsequent LH/FSH secretion. Research applications include HPG axis assessment, reproductive endocrinology and fertility research. Administer subcutaneously per research protocol.

💡 Pulsatile administration is documented in research to maintain receptor sensitivity — continuous infusion studies note desensitisation of kisspeptin receptors.

Based on: Jayasena CN et al. J Clin Invest 2014 — Read study

Oxytocin is an endogenous neuropeptide produced in the hypothalamus, studied for its role in social cognition, stress response modulation, wound healing and neuroendocrine function. Intranasal administration achieves CNS penetration for central research applications. Administer intranasally or subcutaneously per research protocol.

💡 Research notes context-dependent effects and potential receptor downregulation with prolonged continuous administration — intermittent protocols are more commonly documented.

Based on: MacDonald K et al. Harv Rev Psychiatry 2010 — Read study

L-Carnitine is an endogenous quaternary ammonium compound essential for mitochondrial fatty acid transport. Injectable administration bypasses the low oral bioavailability (~14–18%) associated with oral forms. Studied for effects on fat oxidation, exercise metabolism and recovery markers. Administer subcutaneously.

💡 Research protocols typically administer prior to exercise sessions to maximise substrate availability during aerobic metabolism studies.

Based on: Wall BT et al. J Physiol 2011 — Read study

5-Amino-1MQ is a selective, membrane-permeable inhibitor of Nicotinamide N-methyltransferase (NNMT), studied for its effects on NAD+ metabolism, adipogenesis and energy expenditure in preclinical models. Preclinical data demonstrates significant changes in fat mass without caloric restriction. Administer orally or subcutaneously per research protocol.

💡 Frequently studied alongside NAD+ due to complementary mechanisms — NNMT inhibition increases NAD+ availability, creating a synergistic metabolic research combination.

Based on: Neelakantan H et al. Biochemistry 2018 — Read study

SLU-PP-332 is a pan-ERR (oestrogen-related receptor α/β/γ) agonist studied for its effects on mitochondrial biogenesis, oxidative metabolism and exercise-associated gene expression. Preclinical data demonstrates improvements in aerobic capacity and metabolic parameters. Human data remains limited at this stage. Administer subcutaneously.

💡 Research interest centres on ERR agonism as a potential approach to studying exercise-adaptive metabolic pathways without physical activity — commonly referred to as an "exercise mimetic" in literature.

Based on: Zuercher WJ et al. J Med Chem 2005 — Read study